Theriva Biologics Announces Closing of $7.5 Million Public Offering

Core Viewpoint - Theriva Biologics has successfully closed a public offering, raising approximately $7.5 million to support its cancer therapeutics development and other corporate purposes [1][2]. Group 1: Offering Details - The public offering consisted of 6,818,180 shares of common stock and warrants to purchase an equal number of shares at a combined price of$1.10 per share [1]. - The warrants are exercisable immediately and will expire five years from the issuance date [1]. - The offering was conducted under a registration statement that was declared effective by the SEC on May 7, 2025 [3]. Group 2: Use of Proceeds - The net proceeds from the offering will primarily be used for working capital, general corporate purposes, research and development, and manufacturing scale-up [2]. - The company may also consider investing in or acquiring other products, businesses, or technologies, although no commitments currently exist [2]. Group 3: Company Overview - Theriva Biologics is a clinical-stage company focused on developing therapeutics for cancer and related diseases, with a particular emphasis on high unmet medical needs [5]. - The company's lead candidates include VCN-01, SYN-004, and SYN-020, targeting various aspects of cancer treatment and gastrointestinal health [5].